活检初治患者中MRI靶向穿刺与系统随机穿刺的前列腺癌诊断:PRECISION类试验回顾性队列随访
该单中心回顾性研究纳入618例活检初治患者,比较系统随机穿刺(SB组354例)与mpMRI后仅对PI-RADS≥3病灶行靶向穿刺(TB组264例)两条诊断路径。中位随访36个月,两组csPCa ISUP GG≥2(6.1% vs 4.4%,p=0.6)和GG≥3(3.3% vs 1.1%,p=0.2)随访期检出率相似;基线mpMRI阴性(PI-RADS≤2)避免穿刺者随访中仅4.1%检出GG≥2,无GG≥3。
要点
- 初始穿刺TB组csPCa检出率高于SB组,但随访期两组csPCa检出率无显著差异。
- 基线mpMRI阴性者可安全避免前列腺穿刺,随访仅4.1%检出csPCa ISUP GG≥2。
- 基线mpMRI阴性者随访中无csPCa ISUP GG≥3检出。
核心结论
- 活检初治人群中,基于mpMRI仅靶向穿刺可疑病灶的诊断路径,随访期csPCa检出率不高于系统随机穿刺路径。
- 基线mpMRI阴性(PI-RADS≤2)者可安全避免前列腺穿刺,仅需重复PSA随访。
研究设计与样本
- 回顾性单中心研究,纳入618例活检初治患者(2015-2018年),SB组354例,TB组264例。
- TB组行mpMRI后仅对PI-RADS≥3病灶靶向穿刺,PI-RADS≤2者避免前列腺穿刺。
- 采用Kaplan-Meier曲线和单变量Cox回归模型比较两组csPCa ISUP GG≥2和GG≥3的随时间检出率。
主要发现
- 初始穿刺时,TB组csPCa ISUP GG≥2检出率35.3%高于SB组18.9%(p<0.001)。
- 初始穿刺时,TB组csPCa ISUP GG≥3检出率12.6%高于SB组6.2%(p=0.04)。
- 中位随访36个月,SB组与TB组csPCa ISUP GG≥2检出率分别为6.1%与4.4%(p=0.6)。
- 中位随访36个月,SB组与TB组csPCa ISUP GG≥3检出率分别为3.3%与1.1%(p=0.2)。
- TB组中因基线mpMRI阴性(n=145)避免穿刺者,随访仅4.1%检出csPCa ISUP GG≥2,无GG≥3检出。
临床怎么用
- 活检初治患者可考虑先行mpMRI,仅对PI-RADS≥3病灶行靶向穿刺。
- 基线mpMRI阴性(PI-RADS≤2)者可避免前列腺穿刺,采用重复PSA检测随访。
局限性
- 回顾性单中心研究设计。
- 样本量为618例,随访时间中位36个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To test clinically significant prostate cancer (csPCa) rates during follow-up in biopsy naïve patients that underwent two different diagnostic pathways: (1) SB GROUP (n = 354): systematic random biopsies (SB) vs. (2) TB GROUP (n = 264): multiparametric magnetic resonance imaging (mpMRI) and only targeted biopsies (TB) of PI-RADS ≥ 3 lesions. Patients with PI-RADS ≤ 2 score avoided prostate biopsies. METHODS: Retrospective single centre study of 618 biopsy naive patients (2015-2018). Two different definitions of csPCa were used: (1) csPCa ISUP GG ≥ 2 (ISUP grade group [GG] ≥ 2) and (2) csPCa ISUP GG ≥ 3. Kaplan-Meier plots and univariable Cox regression models tested rates over time of csPCa ISUP GG ≥ 2 and caPCa ISUP GG ≥ 3 in SB GROUP vs. TB GROUP. RESULTS: At initial biopsy, TB achieved higher rates of csPCa ISUP GG ≥ 2 (35.3 vs. 18.9%; p < 0.001) and csPCa ISUP GG ≥ 3 (12.6 vs. 6.2%; p = 0.04), relative to SB. After a median time follow-up of 36 months, the rates of csPCa ISUP GG ≥ 2 (6.1 vs. 4.4%; p = 0.6) and csPCa ISUP GG ≥ 3 (3.3 vs. 1.1%; p = 0.2) were similar in SB GROUP vs. TB GROUP. Moreover, in TB GROUP patients that avoided prostate biopsies because of negative baseline mpMRI (n = 145), only 4.1% exhibited csPCa ISUP GG ≥ 2 during follow-up. Moreover, none of these patients (PI-RADS ≤ 2) had csPCa ISUP GG ≥ 3. CONCLUSIONS: In biopsy naïve setting, a diagnostic pathway including pre-biopsy mpMRI and TB of only PCa suspicious lesions is not associated with higher rates of csPCa during follow-up, relative to a diagnostic pathway of SB. Moreover, patients with negative baseline mpMRI could safely avoid prostate biopsies and could be followed with repeated PSA testing, since only a small proportion of them would harbor csPCa.
引用
- Luzzago S, de Cobelli O, Mistretta FA, et al. MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naïve patients: follow-up of a PRECISION trial-like retrospective cohort. Prostate Cancer Prostatic Dis. 2020. PMID: 32989259. doi:10.1038/s41391-020-00290-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。